Foghorn Therapeutics (FHTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FHTX Foghorn Therapeutics

Watchlist

6.598
+0.348+5.57%

Trading Jul 25 12:31 ET

365.06MMarket Cap-2999P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
PR NewswireJul 23 06:00 ET
After Losing 23% in the Past Year, Foghorn Therapeutics Inc. (NASDAQ:FHTX) Institutional Owners Must Be Relieved by the Recent Gain
Simply Wall StJul 15 11:52 ET
Express News | Foghorn Therapeutics Says Flagship Pioneering Raised $3.6B To To Support The Creation And Development Of An Estimated 25 Breakthrough Companies In Human Health
BenzingaJul 10 06:18 ET
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations That Transform Human Health and Sustainability
PR NewswireJul 10 06:00 ET
Flagship Pioneering Expands Leadership Team With Key Appointments and Promotions
PR NewswireJul 10 06:00 ET
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
PR NewswireJun 12 07:00 ET

Comments

Jaguar8

May 20 08:54

$Foghorn Therapeutics(FHTX.US)$
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Trytosaveabit

Apr 9 15:59

Update! Watching

$Foghorn Therapeutics(FHTX.US)$ Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...

Jaguar8

Apr 9 15:32

$Foghorn Therapeutics(FHTX.US)$
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.

Moomoo AI

Mar 10 08:40

Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.